Charles Schwab
ALZN icon

Charles Schwab’s Alzamend Neuro ALZN Stock Holding History

Charles Schwab’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-39
Closed -$12.6K – 3539
2023
Q3 		$12.6K Hold
39
– – ﹤0.01% 3550
2023
Q2 		$27.1K Hold
39
– – ﹤0.01% 3523
2023
Q1 		$22.6K Hold
39
– – ﹤0.01% 3494
2022
Q4 		$30K Buy
+39
New +$56.5K ﹤0.01% 3457

Other funds holding ALZN

Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Charles Schwab's ALZN Position: Q4 2023 in Review

Charles Schwab sold out of Alzamend Neuro (ALZN) in Q4 2023, closing a stake of 39 shares — an estimated $12.6K sold.

Charles Schwab first reported a position in ALZN in Q4 2022 and held it in 4 quarters. The position peaked at $30K in Q4 2022. 14 funds tracked by Wall St. Rank hold ALZN as of Q4 2023.

  • Charles Schwab reported no remaining Alzamend Neuro position as of Q4 2023 after selling out during the quarter.
  • Charles Schwab sold 39 Alzamend Neuro shares in Q4 2023, an estimated $12.6K.
  • Charles Schwab first reported a position in Alzamend Neuro in Q4 2022 and held it in 4 quarters.
  • Charles Schwab's Alzamend Neuro position peaked at $30K in Q4 2022.
  • 14 funds tracked by Wall St. Rank held Alzamend Neuro as of Q4 2023.

Based on Charles Schwab's 13F filing for Q4 2023, filed 6 Feb 2024.